A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

Exclusion Criteria

• •1. Subjects with Clinically significant pulmonary diseases；
• •2. Subjects with other diseases that could lead to elevated eosinophils；
• •3. Subjects with Immunodeficiency；
• •4. Poorly controlled hypertension;
• •5. Subjects with severe cerebrovascular disease;
• •6. Subjects with infection history requiring clinical intervention；
• •7. Subjects with parasitic infection；
• •8. Diagnosed Malignant tumor within 5 years prior to randomization;
• •9. Used non-selective β-blockers within 1 week prior to randomization;
• •10. Used either 5-lipoxygenase inhibitor or Phosphodiesterase-4 inhibitor within 1 week prior to randomization;
• •11. Blood donation or massive blood loss, or transfusion of blood products or immunoglobulins within 4 weeks prior to randomization;
• •12. Live attenuated vaccine inoculated within 4 weeks before randomization;
• •13. Allergen Immunotherapy within 8 weeks prior to randomization；
• •14. Used systemic immunosuppressants or immunomodulators, or biologics or Th2 cytokine inhibitors within 12 weeks prior to randomization or within 5 half-lives of the drug;
• •15. Bronchial thermoplasty within 1 year prior to randomization；
• •16. Subjects have planned Surgery or other medical procedures that may affect evaluation during the study period;
• •17. Subjects with significant laboratory abnormality at screening；
• •18. Subjects have prolonged QTc interval or other electrocardiogram abnormality with significant safety risk at screening;
• •19. Current smokers or ex-smokers who have given up smoking for \<6 months ，or positive smoke test, and/or have a smoking pack history of \> 10 pack years;
• •20. History of drug or substance abuse or alcohol abuse within 1 year prior to screening;
• •21. Subjects participated another clinical studies and received active drug within 30 days or 5 half-lives prior to screening;
• •22. Subjects is pregnant, lactating,or planning to become pregnant;
• •23. Subjects have a known history of hypersensitivity or intolerance to anti-IL-5 mabs or other biological agents;
• •24. Other conditions unsuitable for participation in the study per investigator judgement.